ArcherDX Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 250
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $2.33B
Latest Deal Amount

ArcherDX General Information

Description

Developer of next-generation sequencing-based gene fusion detection assays intended to target enrichment chemistry. The company's assays utilize fusion detection technology with a lyophilized workflow and an advanced analysis pipeline to detect fusions and mutations, enabling researchers to detect and identify fusion partners of assay genes as well as selected indels and point mutations without prior knowledge of fusion partners or breakpoints.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Primary Office
  • 2477 55th Street
  • Suite 202
  • Boulder, CO 80301
  • United States
+1 (303) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ArcherDX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 02-Oct-2020 $2.33B 00000 00.000 Completed Generating Revenue/Not Profitable
9. IPO 23-Jun-2020 00000 Cancelled Generating Revenue/Not Profitable
8. Later Stage VC 30-Apr-2020 00.000 00000 Completed Generating Revenue
7. Later Stage VC (Series C) 17-Dec-2019 0000 00000 00000 Completed Generating Revenue
6. Later Stage VC (Series B) 15-May-2019 0000 000.00 00000 Completed Generating Revenue
5. Debt - General 12-Sep-2018 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 20-Mar-2018 000.00 000.00 000.00 Completed Generating Revenue
3. Spin-Off 01-Dec-2014 Completed Generating Revenue
2. Merger/Acquisition 06-Sep-2013 $50M $1M 0000 Completed Generating Revenue
1. Early Stage VC $1M $1M Completed Startup
To view ArcherDX’s complete valuation and funding history, request access »

ArcherDX Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A 14,780,767 $0.001000 6% $3.56 $3.56 1x $3.56 33.8%
To view ArcherDX’s complete cap table history, request access »

ArcherDX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of next-generation sequencing-based gene fusion detection assays intended to target enrichment chemistry. The
Drug Discovery
Boulder, CO
250 As of 2020
00000
0.000 0000-00-00
000000&0 00000

00000000

x ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000 000000000
Menlo Park, CA
000 As of 0000
00000
0000 0000-00-00
00000000 00000

00000 00

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occa
0000 000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ArcherDX Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Personalis Formerly VC-backed Menlo Park, CA 000 00000 00000000 00000
00000 0000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000000 Venture Capital-Backed Cambridge, United Kingdom 00 000.00 0000000000 0 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
0000 0000000000 Corporation Hayward, CA
You’re viewing 5 of 48 competitors. Get the full list »

ArcherDX Executive Team (12)

Name Title Board Seat Contact Info
Jason Myers Ph.D Co-Founder, Chief Executive Officer & President
Joshua Stahl Chief Operating Officer & Chief Scientific Officer
James Ashby Director of Quality Assurance
Todd Druley Ph.D Chief Medical Officer
Jason Haddock Chief Financial Officer
You’re viewing 5 of 12 executive team members. Get the full list »

ArcherDX Board Members (6)

Name Representing Role Since
Jason Ryan ArcherDX Board Member 000 0000
Kyle Lefkoff Boulder Ventures Board Member 000 0000
Marvin Caruthers Ph.D Self Board Member 000 0000
Paul Manning PBM Capital Group Board Member 000 0000
Steven Kafka Ph.D Self Executive Chairman 000 0000
You’re viewing 5 of 6 board members. Get the full list »

ArcherDX Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ArcherDX Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ArrowMark Partners Asset Manager Minority 000 0000 000000 0
Boulder Ventures Venture Capital Minority 000 0000 000000 0
Driehaus Capital Management Corporation Minority 000 0000 000000 0
Enzymatics Corporation Majority 000 0000 000000 0
Longwood Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

ArcherDX Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000 30-Jan-2019 000000000000000000 Biotechnology 00000 00000 00.0
To view ArcherDX’s complete acquisitions history, request access »